Eposino Special Precautions

During the treatment with epoetin α, the hematocrit should be checked regularly (once a week at the early stage and once every 2 weeks in the maintenance period). The hematocrit should be maintained <30% volume to avoid the formation of extraordinary erythropoiesis. Should extraordinary erythropoiesis happen, suitable treatment shall be taken eg, temporarily discontinuing the use of epoetin α.
Hyperkalemia may appear during the course of treatment, diet should be adjusted or the Eposino should be stopped for use when hyperkalemia occurs until the normal level is recovered.
Eposino should be used carefully for patients with myocardial infarction or to pulmonary infarction or those with allergic history or tendency.
During the treatment with recombinant human erythropoietin α, iron concentration in serum usually decreases. Therefore, it is necessary to provide iron to meet the body's need. If serum ferric concentration is <100 mg/mL or the transfer in saturation falls <20%, daily ferrotherapy should be adopted.
Folic and vitamin B12 insufficiency and ultra-high aluminum may reduce efficacy or Eposino.
Use in Pregnancy & Lactation: The safety for pregnant women or in lactation is not certain.
Use in Children: The safety for children is not certain.
Use in Elderly: For aged patients with complications of hypertension or circulation system because of hypo-function, the blood pressure and hematocrit should be monitored frequently when epoetin α is used. The dosage and times of administration should be adjusted accordingly.